RESUMEN
The parathyroid gland is an endocrine organ that plays a crucial role in regulating calcium levels in blood serum through the secretion of parathyroid hormone (PTH). Hypoparathyroidism is a chronic disease that can occur due to parathyroid defects, but due to the difficulty of creating animal models of this disease or obtaining human normal parathyroid cells, the evaluation of parathyroid functionality for drug development is limited. Although parathyroid-like cells that secrete PTH have recently been reported, their functionality may be overestimated using traditional culture methods that lack in vivo similarities, particularly vascularization. To overcome these limitations, we obtained parathyroid organoids from tonsil-derived mesenchymal stem cells (TMSCs) and fabricated a parathyroid-on-a-chip, capable of simulating PTH secretion based on calcium concentration. This chip exhibited differences in PTH secretion according to calcium concentration and secreted PTH within the range of normal serum levels. In addition, branches of organoids, which are difficult to observe in animal models, were observed in this chip. This could serve as a guideline for successful engraftment in implantation therapies in the future.
Asunto(s)
Calcio , Dispositivos Laboratorio en un Chip , Células Madre Mesenquimatosas , Glándulas Paratiroides , Hormona Paratiroidea , Hormona Paratiroidea/metabolismo , Calcio/metabolismo , Humanos , Glándulas Paratiroides/metabolismo , Glándulas Paratiroides/citología , Células Madre Mesenquimatosas/metabolismo , Células Madre Mesenquimatosas/citología , Organoides/metabolismo , Organoides/citología , Células CultivadasRESUMEN
Differentiation of human embryonic stem cells (hESCs) into human embryonic stem cells-derived parathyroid-like cells (hESC-PT) has clinical significance in providing new therapies for congenital and acquired parathyroid insufficiency conditions. However, a highly reproducible, well-documented method for parathyroid differentiation remains unavailable. By imitating the natural process of parathyroid embryonic development, we proposed a new hypothesis about the in vitro differentiation of parathyroid-like cells. Transcriptome, differentiation marker protein detection and parathyroid hormone (PTH) secretion assays were performed after the completion of differentiation. To optimize the differentiation protocol and further improve the differentiation rate, we designed glial cells missing transcription factor 2 (GCM2) overexpression lentivirus transfection assays and constructed hESCs-derived parathyroid organoids. The new protocol enabled hESCs to differentiate into hESC-PT. HESC-PT cells expressed PTH, GCM2 and CaSR proteins, low extracellular calcium culture could stimulate hESC-PT cells to secrete PTH. hESC-PT cells overexpressing GCM2 protein secreted PTH earlier than their counterpart hESC-PT cells. Compared with the two-dimensional cell culture environment, hESCs-derived parathyroid organoids secreted more PTH. Both GCM2 lentiviral transfection and three-dimensional cultures could make hESC-PT cells functionally close to human parathyroid cells. Our study demonstrated that hESCs could differentiate into hESC-PT in vitro, which paves the road for applying the technology to treat hypoparathyroidism and introduces new approaches in the field of regenerative medicine.
Asunto(s)
Diferenciación Celular , Células Madre Embrionarias Humanas , Organoides , Glándulas Paratiroides , Hormona Paratiroidea , Factores de Transcripción , Humanos , Organoides/citología , Organoides/metabolismo , Células Madre Embrionarias Humanas/citología , Células Madre Embrionarias Humanas/metabolismo , Glándulas Paratiroides/citología , Glándulas Paratiroides/metabolismo , Hormona Paratiroidea/metabolismo , Factores de Transcripción/metabolismo , Factores de Transcripción/genética , Células Cultivadas , Técnicas de Cultivo de Célula/métodos , Proteínas NuclearesRESUMEN
Hypoparathyroidism is an endocrine disorder characterized by low serum calcium levels, high serum phosphorus levels, and by inappropriate or absent secretion of the parathyroid hormone (PTH). The most common therapeutic strategy to treat this condition is hormone replacement therapy with calcium and vitamin D but, unfortunately, in the long term this treatment may not be sufficient to compensate for the loss of endocrine function. Glandular autotransplantation is considered the most effective technique in place of replacement therapy. Although it leads to excellent results in most cases, autotransplantation is not always possible. Allograft is a good way to treat patients who have not been able to undergo autograft, but this technique has limited success due to side effects related to tissue rejection. This therapy is supported by systemic immunosuppression, which leads to the onset of serious side effects in patients, with a risk of endocrine toxicity. Today, research on endocrine disorders is focused on discovering alternative graft therapies that can allow optimal results with the fewest possible side effects. In this review, we will make an update on the current state of the art about the cell and tissue therapy as treatment for hypoparathyroidism, to identify which type of therapeutic strategy could be valid for a future clinical use.
Asunto(s)
Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Hipoparatiroidismo/terapia , Animales , Encapsulación Celular , Tratamiento Basado en Trasplante de Células y Tejidos/tendencias , Humanos , Hipoparatiroidismo/etiología , Hipoparatiroidismo/fisiopatología , Glándulas Paratiroides/citología , Glándulas Paratiroides/trasplante , Medicina Regenerativa , Trasplante de Células Madre , Trasplante Autólogo , Trasplante HomólogoRESUMEN
BACKGROUND: The role of oxyphil cells (OxC) in primary hyperparathyroidism (PHPT) still remains controversial. Historically, they were believed to be involuted cells. However, they could play an important role in hormone secretion. The clinical behavior of OxC-rich adenomas and preoperative PHPT localization tests have been widely studied. The aim of this study is to analyze the implications of OxC in PHTP. METHODS: A retrospective cohort study of patients undergoing parathyroidectomy for PHPT was conducted. Additionally, we included normal glands removed in the context of PHPT or inadvertently during a thyroidectomy. All glands were reviewed independently by three researchers, performing a semi-quantitative analysis of the percentage of OxC. Groups with < 25% OxC and > 75% OxC were compared. RESULTS: In the period 2010-2017, 238 patients and 261 removed glands were included (8.8% OxCA > 75%). There were no differences in symptomatology and levels of preoperative calcium, parathormone, or 25-OH vitamin. Patients with OxCA > 75% had worse preoperative glomerular filtration rate (81.2 vs. 69.7 mL/min/1.73 m2; p = 0.043). They also had a trend towards larger size and weight (17 vs. 20 mm, p = 0.135 and 562 vs. 875 mg, p = 0.495), while ultrasound was found to have better accuracy (48.3% vs. 73.7%; p = 0.035). There were no normal glands with a content of OxC > 75%. CONCLUSIONS: Our study suggests that phosphocalcic metabolism is not influenced by the presence of a high content of OxC in the parathyroid glands. A high content of OxC seems to be exclusive to pathologic glands and could be related to the deterioration of renal function in patients with PHPT.
Asunto(s)
Hiperparatiroidismo Primario , Células Oxífilas , Glándulas Paratiroides/citología , Humanos , Hiperparatiroidismo Primario/cirugía , Glándulas Paratiroides/patología , Hormona Paratiroidea , Paratiroidectomía , Estudios RetrospectivosRESUMEN
Differentiation of pluripotent stem cells into functional parathyroid-like cells would accelerate development of important therapeutic options for subjects with parathyroid-related disorders, from the design and screening of novel pharmaceutical agents to the development of durable cellular therapies. We have established a highly reproducible directed differentiation approach leading to PTH-expressing cells from human embryonic stem cells and induced pluripotent stem cells. We accomplished this through the comparison of multiple different basal media, the inclusion of the CDK inhibitor PD0332991 in both definitive endoderm and anterior foregut endoderm stages, and a 2-stage pharyngeal endoderm series. This is the first protocol to reproducibly establish PTH-expressing cells from human pluripotent stem cells and represents a first step toward the development of functional parathyroid cells with broad applicability for medicinal and scientific investigation.
Asunto(s)
Diferenciación Celular/genética , Células Madre Embrionarias Humanas/fisiología , Glándulas Paratiroides/embriología , Hormona Paratiroidea/genética , Células Madre Pluripotentes/fisiología , Células Cultivadas , Endodermo/citología , Endodermo/metabolismo , Regulación del Desarrollo de la Expresión Génica/fisiología , Células Madre Embrionarias Humanas/citología , Células Madre Embrionarias Humanas/metabolismo , Humanos , Organogénesis/genética , Glándulas Paratiroides/citología , Hormona Paratiroidea/metabolismo , Células Madre Pluripotentes/metabolismoRESUMEN
Parathyroidectomy is a standard practice to treat recurrent or persistent hyperparathyroidism. However, this can lead to the onset of hypoparathyroidism, treatable with the autotransplantation of parathyroid tissue (PT). Tissue can be transplanted immediately after parathyroidectomy or cryopreserved and transplanted only in case of necessity. Since 2011, the Cord Blood Bank and Cardiovascular Tissue Bank of Emilia-Romagna has been storing PT for potential autologous transplantation. To date, there are highly variable data about the viability and function of PT after thawing. However, it is not clear if the PT quality is affected by different cryopreservation protocols and/or by the storage time. The aim of this study was to assess the ex vivo function and viability of the PTs of ten patients stored in the Bank. Tissue morphology was evaluated before and after cryopreservation through histological investigations. PT function was analyzed by assessing the ability of cryopreserved PT to synthesize and secrete parathyroid hormone (PTH) in response to different calcium concentrations. Moreover, viability and function were also investigated on tissue-isolated cells in culture. These data show that tested tissues appear to be viable and able to produce PTH even after 5 years of storage, and the histological architecture is well preserved.
Asunto(s)
Criopreservación/métodos , Hiperparatiroidismo/cirugía , Glándulas Paratiroides/citología , Humanos , Hipoparatiroidismo/terapia , Glándulas Paratiroides/metabolismo , Hormona Paratiroidea/metabolismo , Paratiroidectomía/efectos adversos , Bancos de Tejidos , Técnicas de Cultivo de Tejidos , Supervivencia Tisular , Trasplante AutólogoRESUMEN
Permanent hypoparathyroidism is a severe clinical condition accompanied by low parathyroid hormone level. Conventional treatment requires lifelong medication, and daily drug usage has some side effects. To avoid this circumstance, transplantation is an alternative and curative option. Microencapsulation may be used as a transplantation approach particularly to evade immune response. In order to define treatment of permanent hypoparathyroidism, a 37-year-old female recipient who has permanent hypoparathyroidism was evaluated for 3 years. Routine tests, viral markers, and T and B lymphocyte cross-match tests were analyzed. In addition intradermal skin test was performed for ultrapure alginate. Microencapsulation of cultured parathyroid cells was performed with ultrapure alginate. Cell suspension was prepared and spheroids were generated with calcium chloride. Afterward, transplantation was performed with a laparoscopic approach in the omental tissue. The recipient was discharged from the hospital without complications. Serum calcium, parathyroid hormone (PTH), and phosphorus levels were observed throughout 1 year. During the follow-up period, no complications were observed. Serum calcium levels were increased significantly on day 10 and PTH levels were increased on day 25 as well. According to our knowledge, this is the first study where ultrapure alginate-based microencapsulated parathyroid cells were transplanted in the omental tissue. A significant increment of PTH levels was detected. Microencapsulated parathyroid cells showed the functionality of this technique for more than 1 year. This study showed that using ultrapure alginate-based microencapsulation without immunosuppression appears to be a promising technique.
Asunto(s)
Encapsulación Celular/métodos , Células Inmovilizadas/trasplante , Hipoparatiroidismo/terapia , Glándulas Paratiroides/citología , Glándulas Paratiroides/trasplante , Adulto , Alginatos/química , Separación Celular , Células Cultivadas , Células Inmovilizadas/citología , Femenino , Humanos , Hipoparatiroidismo/cirugía , Masculino , Epiplón/citología , Epiplón/cirugíaRESUMEN
Ligustroflavone is one major compound contained in active fraction from Fructus Ligustri Lucidi (the fruit of Ligustrum lucidum), which could regulate parathyroid hormone (PTH) levels and improve calcium balance by acting on calcium-sensing receptors (CaSR). This study aimed to explore the potency of ligustroflavone as a CaSR antagonist and its protective effects against diabetic osteoporosis in mice. LF interacted well with the allosteric site of CaSR shown by molecular docking analysis, increased PTH release of primary parathyroid gland cells and suppressed extracellular calcium influx in HEK-293 cells. The serum level of PTH attained peak value at 2 h and maintained high during the period of 1 h and 3 h than that before treatment in mice after a single dose of LF. Treatment of diabetic mice with LF inhibited the decrease in calcium level of serum and bone and the enhancement in urinary calcium excretion as well as elevated circulating PTH levels. Trabecular bone mineral density and micro-architecture were markedly improved in diabetic mice upon to LF treatment for 8 weeks. LF reduced CaSR mRNA and protein expression in the kidneys of diabetic mice. Taken together, ligustroflavone could transiently increase PTH level and regulate calcium metabolism as well as prevent osteoporosis in diabetic mice, suggesting that ligustroflavone might be an effective antagonist on CaSR.
Asunto(s)
Apigenina/farmacología , Complicaciones de la Diabetes/complicaciones , Glicósidos/farmacología , Ligustrum/química , Osteoporosis/etiología , Osteoporosis/prevención & control , Receptores Sensibles al Calcio/antagonistas & inhibidores , Animales , Apigenina/administración & dosificación , Apigenina/aislamiento & purificación , Densidad Ósea/efectos de los fármacos , Calcio/metabolismo , Hueso Esponjoso/metabolismo , Células Cultivadas , Expresión Génica/efectos de los fármacos , Glicósidos/administración & dosificación , Glicósidos/aislamiento & purificación , Células HEK293 , Humanos , Riñón/metabolismo , Masculino , Ratones Endogámicos C57BL , Glándulas Paratiroides/citología , Glándulas Paratiroides/metabolismo , Hormona Paratiroidea/metabolismo , Receptores Sensibles al Calcio/genética , Receptores Sensibles al Calcio/metabolismo , Factores de TiempoRESUMEN
Glial cells missing homolog 2 (GCM2), a zinc finger-type transcription factor, is essential for the development of parathyroid glands. It is considered to be a master regulator because the glands do not form when Gcm2 is deficient. Remarkably, Gcm2 expression is maintained throughout the fetal stage and after birth. Considering the Gcm2 function in embryonic stages, it is predicted that Gcm2 maintains parathyroid cell differentiation and survival in adults. However, there is a lack of research regarding the function of Gcm2 in adulthood. Therefore, we analyzed Gcm2 function in adult tamoxifen-inducible Gcm2 conditional knockout mice. One month after tamoxifen injection, Gcm2-knockout mice showed no significant difference in serum calcium, phosphate, and PTH levels and in the expressions of calcium-sensing receptor (Casr) and parathyroid hormone (Pth), whereas Ki-67 positive cells were decreased and terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) positive cell number did not change, as compared with those of controls. Seven months after tamoxifen injection, Gcm2-knockout mice showed shrinkage of the parathyroid glands and fewer parathyroid cells. A significant decrease was noted in Casr- and Pth-expressing cells and serum PTH and Ca levels, whereas serum phosphate levels increased, as compared with those of controls. All our results concluded that a reduction of Gcm2 expression leads to a reduction of parathyroid cell proliferation, an increase in cell death, and an attenuation of parathyroid function. Therefore, we indicate that Gcm2 plays a prominent role in adult parathyroid cell proliferation and maintenance.
Asunto(s)
Proteínas Nucleares/metabolismo , Glándulas Paratiroides/citología , Glándulas Paratiroides/metabolismo , Factores de Transcripción/metabolismo , Animales , Proliferación Celular/efectos de los fármacos , Femenino , Técnicas de Genotipaje , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Masculino , Ratones , Ratones Noqueados , Proteínas Nucleares/genética , Glándulas Paratiroides/efectos de los fármacos , Factores de Transcripción/genéticaRESUMEN
BACKGROUND: Cold ischemia protects organs and tissues by slowing their metabolism, but it also causes ischemic injury. Minimizing cold ischemia has been an important goal in parathyroid auto- and allotransplantation, as well as the transplantation of other major organs. Parathyroid glands are responsible for calcium homeostasis by releasing parathormone (PTH) into the blood circulation. Functionality of a new parathyroid transport solution (NPTS) and effects on cell viability, PTH secretion, and calcium-sensing receptor (CaSR) levels during cold ischemia were evaluated. MATERIALS AND METHODS: A NPTS was prepared, and the pH was adjusted to a range of 7.2-7.4 and kept at +4°C until use. Seven patients with parathyroid hyperplasia secondary to chronic renal failure who were scheduled to undergo subtotal parathyroidectomy were enrolled in the study. Glands were cold-preserved in NPTS with different time intervals (0, 6, 12, 18, and 24 hours), and then parathyroid cell viability before and after cryopreservation, PTH secretion, and CaSR levels were determined. RESULTS: The mean cell viability before cryopreservation was 92.7% (range 89.2%-97.2%). There were no significant differences in cell viability rates before and after cryopreservation (p = 0.1168 and p = 0.4085, respectively), and CaSR levels (p = 0.5446) were not significant. CONCLUSIONS: NPTS is a solution designed specifically for parathyroid tissue transplantation. This patent pending product can support cellular viability and PTH release, as well as protect CaSR functionality for up to 24 hours of cold ischemia.
Asunto(s)
Criopreservación/métodos , Receptores Sensibles al Calcio/metabolismo , Aminoácidos/química , Western Blotting , Supervivencia Celular/fisiología , Células Cultivadas , Humanos , Concentración de Iones de Hidrógeno , Glándulas Paratiroides/citología , Hormona Paratiroidea/químicaRESUMEN
The avian embryo, as an experimental model, has been of utmost importance for seminal discoveries in developmental biology. Among several approaches, the formation of quail-chicken chimeras and the use of the chorioallantoic membrane (CAM) to sustain the development of ectopic tissues date back to the last century. Nowadays, the combination of these classical techniques with recent in vitro methodologies offers novel prospects to further explore organ formation. Here we describe a two-step approach to study early- and late-stages of organogenesis. Briefly, the embryonic region containing the presumptive territory of the organ is isolated from quail embryos and grown in vitro in an organotypic system (up to 48 h). Cultured tissues are subsequently grafted onto the CAM of a chicken embryo. After 10 days of in ovo development, fully formed organs are obtained from grafted tissues. This method also allows the modulation of signaling pathways by the regular administration of pharmacological agents and tissue genetic manipulation throughout in vitro and in ovo developmental steps. Additionally, developing tissues can be collected at any time-window to analyze their gene-expression profile (using quantitative PCR (qPCR), microarrays, etc.) and morphology (assessed with conventional histology and immunochemistry). The described experimental procedure can be used as a tool to follow organ formation outside the avian embryo, from the early stages of organogenesis to fully formed and functional organs.
Asunto(s)
Pollos/crecimiento & desarrollo , Organogénesis/genética , Glándulas Paratiroides/metabolismo , Codorniz/crecimiento & desarrollo , Timo/metabolismo , Animales , Glándulas Paratiroides/citología , Timo/citologíaRESUMEN
Primary hyperparathyroidism (PHPT) is defined by inappropriate elevation of parathormone, caused by parathyroid hyperplasia, also known as multi-gland disease (MGD), parathyroid adenoma (PA), or parathyroid carcinoma (PC). Although several studies have already been conducted, there is a lack of a definite diagnostic marker, which could unambiguously distinguish MGD from PA or PC. The accurate and prompt diagnosis has the key meaning for effective treatment and follow-up. This review paper presents the role of apoptosis in PHPT. The comparison of the expression of Fas, TRAIL, BCL-2 family members, p53 in MGD, PA, and PC, among others, was described. The expression of described factors varies among proliferative lesions of parathyroid gland; therefore, these could serve as additional markers to assist in the diagnosis.
Asunto(s)
Proteínas Reguladoras de la Apoptosis/análisis , Apoptosis , Hiperparatiroidismo Primario/patología , Glándulas Paratiroides/patología , Neoplasias de las Paratiroides/patología , Proteínas Reguladoras de la Apoptosis/metabolismo , Biomarcadores/análisis , Biomarcadores/metabolismo , Humanos , Hiperparatiroidismo Primario/diagnóstico , Hiperplasia/diagnóstico , Hiperplasia/patología , Glándulas Paratiroides/citología , Neoplasias de las Paratiroides/diagnósticoRESUMEN
The parathyroid oxyphil cell content increases in patients with chronic kidney disease (CKD), and even more in patients treated with the calcimimetic cinacalcet and/or calcitriol for hyperparathyroidism. Oxyphil cells have significantly more calcium-sensing receptors than chief cells, suggesting that the calcium-sensing receptor and calcimimetics are involved in the transdifferentiation of a chief cell to an oxyphil cell type. Here, we compared the effect of the vitamin D analog paricalcitol (a less calcemic analog of calcitriol) and/or cinacalcet on the oxyphil cell content in patients with CKD to further investigate the genesis of these cells. Parathyroid tissue from four normal individuals and 27 patients with CKD who underwent parathyroidectomy for secondary hyperparathyroidism were analyzed. Prior to parathyroidectomy, patients had received the following treatment: seven with no treatment, seven with cinacalcet only, eight with paricalcitol only, or cinacalcet plus paricalcitol in five. Oxyphilic areas of parathyroid tissue, reported as the mean percent of total tissue area per patient, were normal, 1.03; no treatment, 5.3; cinacalcet, 26.7 (significant vs. no treatment); paricalcitol, 6.9 (significant vs. cinacalcet; not significant vs. no treatment); and cinacalcet plus paricalcitol, 12.7. Cinacalcet treatment leads to a significant increase in parathyroid oxyphil cell content but paricalcitol does not, reinforcing a role for the calcium-sensing receptor activation in the transdifferentiation of chief-to-oxyphil cell type. Thus, two conventional treatments for hyperparathyroidism have disparate effects on parathyroid composition, and perhaps function. This finding is provocative and may be useful when evaluating future drugs for hyperparathyroidism.
Asunto(s)
Calcimiméticos/farmacología , Cinacalcet/farmacología , Ergocalciferoles/farmacología , Hiperparatiroidismo Secundario/terapia , Células Oxífilas/efectos de los fármacos , Glándulas Paratiroides/efectos de los fármacos , Insuficiencia Renal Crónica/tratamiento farmacológico , Adulto , Calcimiméticos/uso terapéutico , Calcitriol/análogos & derivados , Transdiferenciación Celular/efectos de los fármacos , Cinacalcet/uso terapéutico , Quimioterapia Combinada/métodos , Ergocalciferoles/uso terapéutico , Femenino , Humanos , Hiperparatiroidismo Secundario/etiología , Hiperparatiroidismo Secundario/orina , Masculino , Persona de Mediana Edad , Glándulas Paratiroides/citología , Glándulas Paratiroides/metabolismo , Glándulas Paratiroides/cirugía , Paratiroidectomía , Receptores Sensibles al Calcio/metabolismo , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/orina , Uremia/complicaciones , Uremia/tratamiento farmacológico , Uremia/orina , Vitamina D/análogos & derivadosRESUMEN
Water clear cell adenoma of the parathyroid gland is a rare neoplasm composed of large clear cells with foamy cytoplasm and mild nuclear pleomorphism, compressing the residual nonneoplastic parathyroid tissue. The differential diagnosis includes a variety of neoplasms with clear cell features. In this article, we provide an overview of the entity with a historical perspective, in order to help pathologists in distinguishing it from other neoplasms in their daily practice.
Asunto(s)
Adenoma/patología , Hiperparatiroidismo Primario/patología , Neoplasias de las Paratiroides/patología , Enfermedades Raras/patología , Adenoma/diagnóstico , Adenoma/cirugía , Carcinoma de Células Renales/diagnóstico , Carcinoma de Células Renales/patología , Citoplasma/patología , Diagnóstico Diferencial , Humanos , Microscopía Electrónica , Glándulas Paratiroides/citología , Glándulas Paratiroides/patología , Glándulas Paratiroides/ultraestructura , Neoplasias de las Paratiroides/diagnóstico , Neoplasias de las Paratiroides/cirugía , Neoplasias de las Glándulas Salivales/diagnóstico , Neoplasias de las Glándulas Salivales/patologíaRESUMEN
Cell encapsulation is an alternative to avoid rejection of grafted tissue, thus bringing an interesting alternative in cell therapy. It is particularly relevant in ailments where only the implant of small quantities of tissues is warranted. In such circumstances, the use of immunosuppressive therapy in patients implanted with tissues from donors is debatable, yet unavoidable at present in order to prevent rejection and/or sensitization of the host to the tissue, in turn jeopardizing the success of successive implants. Hence, a new line of thought, which aims to provide an immunoprivileged site for the grafted tissue, while at the same time insure its nutrition, as well as its survival and continued function, appears as a most attractive possibility. To achieve these goals, cells or tissues harvested for transplant could be encapsulated in biologically compatible matrices. Among the matrices currently in existence, sodium alginate is the most widely used polymer for tissue encapsulation.In the present chapter, we present a technique used to encapsulate parathyroid tissue, for use as cell transplant therapy in patients with secondary hypoparathyroidism. With this procedure, implanted tissue survives and remains functional for up to 18 months.
Asunto(s)
Alginatos/química , Células Inmovilizadas/citología , Hipoparatiroidismo/terapia , Glándulas Paratiroides/citología , Cápsulas/química , Técnicas de Cultivo de Célula/métodos , Células Cultivadas , Células Inmovilizadas/trasplante , Criopreservación/métodos , Composición de Medicamentos/métodos , Ácido Glucurónico/química , Ácidos Hexurónicos/química , Humanos , Glándulas Paratiroides/trasplante , Conservación de Tejido/métodosRESUMEN
Vitamin D receptor (VDR) agonists (VDRAs) are commonly used to treat secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). Current VDRA therapy often causes hypercalcemia, which is a critical risk for vascular calcification. Previously we have shown that a novel VDRA, VS-105, effectively suppresses serum parathyroid hormone (PTH) without affecting serum calcium levels in 5/6 nephrectomized (NX) uremic rats. However, it is not known whether VS-105 directly regulates PTH gene expression. To study the direct effect of VS-105 on modulating PTH, we tested VS-105 and paricalcitol in the spheroid culture of parathyroid cells from human SHPT patients, and examined the time-dependent effect of the compounds on regulating serum PTH in 5/6 NX uremic rats (i.p. 3x/week for 14days). In human parathyroid cells, VS-105 (100nM) down-regulated PTH mRNA expression (to 3.6% of control) and reduced secreted PTH (to 43.9% of control); paricalcitol was less effective. VS-105 effectively up-regulated the expression of VDR (1.9-fold of control) and CaSR (1.8-fold of control) in spheroids; paricalcitol was also less effective. In 5/6 NX rats, one single dose of 0.05-0.2µg/kg of VS-105 or 0.02-0.04µg/kg of paricalcitol effectively reduced serum PTH by >40% on Day 2. Serum PTH remained suppressed during the dosing period, but tended to rebound in the paricalcitol groups. These data indicate that VS-105 exerts a rapid effect on suppressing serum PTH, directly down-regulates the PTH gene, and modulates PTH, VDR and CaSR gene expression more effectively than paricalcitol.
Asunto(s)
Calcitriol/análogos & derivados , Riñón/metabolismo , Glándulas Paratiroides/metabolismo , Hormona Paratiroidea/sangre , Receptores de Calcitriol/agonistas , Receptores de Calcitriol/metabolismo , Animales , Calcitriol/química , Regulación hacia Abajo , Ergocalciferoles/química , Masculino , Nefrectomía , Glándulas Paratiroides/citología , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Esferoides Celulares/metabolismoRESUMEN
Hypoparathyroidism is characterized by decreased function of the parathyroid glands with underproduction of parathyroid hormone (PTH), which can lead to low levels of calcium in the blood, often causing cramping and twitching of muscles or tetany, and several other symptoms. Severe hypocalcemia is a life-threatening condition. At present, both medical and surgical treatments are offered to improve the blood calcium, but they are not a cure. Adipose-derived stem cells (ADSCs), derived from the adipose tissue, are confirmed to be multipotent with adipogenic, chondrogenic, neurogenic, myogenic and osteogenic capabilities. Our hypothesis is that human ADSCs in culture can be differentiated into parathyroid cells, and used to reconstitute function.
Asunto(s)
Adipocitos/citología , Hipoparatiroidismo/metabolismo , Hipoparatiroidismo/terapia , Glándulas Paratiroides/citología , Células Madre/citología , Adipogénesis , Tejido Adiposo/citología , Animales , Calcio/sangre , Diferenciación Celular , Humanos , Hipocalcemia/sangre , Modelos Teóricos , Osteogénesis , Hormona Paratiroidea/metabolismoRESUMEN
Persistent hypoparathyroidism, a condition associated with major inconvenience and potential morbidity, is more difficult to treat than other hypofunctional endocrine disorders. Therapeutic alternative in severe postsurgical hypoparathyroidism is allotransplantation of macroencapsulated parathyroid cells. With this technique, it is possible to implant cells or tissues of parathyroid origin to replace them in such patients without immunosuppression. At the present time, durable results have only been reported in parathyroid allotransplantation when immunosuppression to prevent rejection is administered. We report an allotransplant of parathyroid cells in a patient with continuous endovenous requirement of calcium to survive. Macrocapsule containing ~(20 to 30)x106 parathyroid cells was constructed with a polyvinylidine difluoride and implanted into the deep femoral artery. The functional activity of the graft, traced for 3 months, allowed to exclude the parenteral administration of calcium and to compensate symptoms of the disease. SIMILAR CASES PUBLISHED: There have been no more than 3 previous clinical reports of similar parathyroid cell allotransplantation without immunosuppression.
Asunto(s)
Trasplante de Células/métodos , Hipoparatiroidismo/terapia , Glándulas Paratiroides/citología , Complicaciones Posoperatorias/terapia , Adulto , Calcio/administración & dosificación , Femenino , Arteria Femoral , Humanos , Hipoparatiroidismo/etiología , Hipoparatiroidismo/patología , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
We compared (18)F-fluorocholine hybrid positron emission tomography/X-ray computed tomography (FCH-PET/CT) with ultrasonography (US) and scintigraphy in patients with hyperparathyroidism and discordant, or equivocal results of US and (123)I/(99m)Tc-sesta-methoxyisobutylisonitrile (sestaMIBI) dual-phase parathyroid scintigraphy. FCH-PET/CT was performed in 17 patients with primary (nâ=â11) lithium induced (nâ=â1) or secondary hyperparathyroidism (1 dialyzed, 4 renal-transplanted).The reference standard was based on results of surgical exploration and histopathological examination. The results of imaging modalities were evaluated, on site and by masked reading, on per-patient and per-lesion bases.In a first approach, equivocal images/foci were considered as negative. On a per-patient level, the sensitivity was for US 38%, for scintigraphy 69% by open and 94% by masked reading, and for FCH-PET/CT 88% by open and 94% by masked reading. On a per-lesion level, sensitivity was for US 42%, for scintigraphy 58% by open and 83% by masked reading, and for FCH-PET/CT 88% by open and 96% by masked reading. One ectopic adenoma was missed by the 3 imaging modalities. Considering equivocal images/foci as positive increased the accuracy of the open reading of scintigraphy or of FCH-PET/CT, but not of US. FCH-PET/CT was significantly superior to US in all approaches, whereas it was more sensitive than scintigraphy only for open reading considering equivocal images/foci as negative (Pâ=â0.04). FCH uptake was more intense in adenomas than in hyperplastic parathyroid glands. Thyroid lesions were suspected in 9 patients. They may induce false-positive results as in one case of oncocytic thyroid adenoma, or false-negative results as in one case of intrathyroidal parathyroid adenoma. Thyroid cancer (4 cases) can be visualized with FCH as with (99m)Tc-sestaMIBI, but the intensity of uptake was moderate, similar to that of parathyroid hyperplasia.This pilot study confirmed that FCH-PET/CT is an adequate imaging tool in patients with primary or secondary hyperparathyroidism, since both adenomas and hyperplastic parathyroid glands can be detected. The sensitivity of FCH-PET/CT was better than that of US and was not inferior to that of dual-phase dual-isotope (123)I/(99m)Tc-scintigraphy. Further studies should evaluate whether FCH could replace (99m)Tc-sestaMIBI as the functional agent for parathyroid imaging, but US would still be useful to identify thyroid lesions.
Asunto(s)
Diagnóstico por Imagen/métodos , Diagnóstico por Imagen/normas , Hiperparatiroidismo Primario/cirugía , Hiperparatiroidismo Secundario/cirugía , Glándulas Paratiroides/citología , Colina/análogos & derivados , Femenino , Humanos , Masculino , Proyectos Piloto , Tomografía de Emisión de Positrones/métodos , Periodo Preoperatorio , Cintigrafía/métodos , Cintigrafía/normas , Radiofármacos , Tecnecio Tc 99m Sestamibi , Tomografía Computarizada por Rayos X , Ultrasonografía/métodos , Ultrasonografía/normasRESUMEN
The study objective was to investigate the effects of fluoride on intact parathyroid hormone (iPTH) secretion. Thyro-parathyroid complexes (TPC) from C3H (n = 18) and B6 (n = 18) mice were cultured in Ca²âº-optimized medium. TPC were treated with 0, 250, or 500 µM NaF for 24 h and secreted iPTH assayed by ELISA. C3H (n = 78) and B6 (n = 78) mice were gavaged once with distilled or fluoride (0.001 mg [Fâ»]/g of body weight) water. At serial time points (0.5-96 h) serum iPTH, fluoride, total calcium, phosphorus, and magnesium levels were determined. Expression of genes involved in mineral regulation via the bone-parathyroid-kidney (BPK) axis, such as parathyroid hormone (Pth), calcium-sensing receptor (Casr), vitamin D receptor (Vdr), parathyroid hormone-like hormone (Pthlh), fibroblast growth factor 23 (Fgf23), α-Klotho (αKlotho), fibroblast growth factor receptor 1c (Fgf1rc), tumor necrosis factor 11 (Tnfs11), parathyroid hormone receptor 1 (Pth1r), solute carrier family 34 member 1 (Slc34a1), solute carrier 9 member 3 regulator 1 (Slc9a3r1), chloride channel 5 (Clcn5), and PDZ domain-containing 1 (Pdzk1), was determined in TPC, humeri, and kidneys at 24 h. An in vitro decrease in iPTH was seen in C3H and B6 TPC at 500 µM (p < 0.001). In vivo levels of serum fluoride peaked at 0.5 h in both C3H (p = 0.002) and B6 (p = 0.01). In C3H, iPTH decreased at 24 h (p < 0.0001), returning to baseline at 48 h. In B6, iPTH increased at 12 h (p < 0.001), returning to baseline at 24 h. Serum total calcium, phosphorus, and magnesium levels did not change significantly. Pth, Casr,αKlotho,Fgf1rc,Vdr, and Pthlh were significantly upregulated in C3H TPC compared to B6. In conclusion, the effects of fluoride on TPC in vitro were equivalent between the 2 mouse strains. However, fluoride demonstrated an early strain-dependent effect on iPTH secretion in vivo. Both strains demonstrated differences in the expression of genes involved in the BPK axis, suggesting a possible role in the physiologic handling of fluoride.